U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H27FN4O2
Molecular Weight 410.4845
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RISPERIDONE

SMILES

CC1=C(CCN2CCC(CC2)C3=NOC4=C3C=CC(F)=C4)C(=O)N5CCCCC5=N1

InChI

InChIKey=RAPZEAPATHNIPO-UHFFFAOYSA-N
InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3

HIDE SMILES / InChI

Molecular Formula C23H27FN4O2
Molecular Weight 410.4845
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Risperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors. It is FDA approved for the treatment of schizophrenia, bipolar mania, irritability associated with autistic disorder. Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. Vice versa, Fluoxetine, paroxetine, and other CYP 2D6 enzyme inhibitors increase plasma concentrations of risperidone. Common adverse reactions include increased mortality in elderly patients with dementia-related psychosis, cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis, neuroleptic malignant syndrome, tardive dyskinesia , metabolic Changes (hyperglycemia and diabetes mellitus, dyslipidemia, weight gain), hyperprolactinemia, orthostatic hypotension, leukopenia, neutropenia, agranulocytosis, potential for cognitive and motor impairment, seizures, dysphagia, priapism, disruption of body temperature regulation.

CNS Activity

Approval Year

PubMed

PubMed

TitleDatePubMed
Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders.
2000 Dec
[Neuropsychiatric symptoms in preventive antimalarial treatment with mefloquine: apropos of 2 cases].
2000 Jul-Aug
Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs.
2000 Nov
Risperidone-associated hyperprolactinemia.
2000 Nov-Dec
Weight change and atypical antipsychotic treatment in patients with schizophrenia.
2001
Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.
2001
Antipsychotic medications and the elderly: effects on cognition and implications for use.
2001
Olanzapine: an updated review of its use in the management of schizophrenia.
2001
Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
2001
Novel treatments for bipolar disorder.
2001 Apr
Protein thiol oxidation by haloperidol results in inhibition of mitochondrial complex I in brain regions: comparison with atypical antipsychotics.
2001 Apr
Health care utilization in patients with schizophrenia maintained on atypical versus conventional antipsychotics.
2001 Feb
Dose relationship of limbic-cortical D2-dopamine receptor occupancy with risperidone.
2001 Feb
Addition of risperidone to clozapine therapy in chronically psychotic inpatients.
2001 Feb
Priapism associated with polypharmacy.
2001 Feb
Weight gain with risperidone among patients with mental retardation: effect of calorie restriction.
2001 Feb
Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels.
2001 Feb
Drug induced akathisia, suicidal ideation and its treatment in the elderly.
2001 Feb
Tolerability and effectiveness of atypical antipsychotics in male geriatric inpatients.
2001 Feb
Combination risperidone and quetiapine therapy in refractory schizophrenia.
2001 Feb
A case of risperidone-induced stuttering.
2001 Feb
Atypical antipsychotics and cardiovascular risk in schizophrenic patients.
2001 Feb
Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity.
2001 Feb
Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.
2001 Feb
Hyperthermia and chronic pancerebellar syndrome after cocaine abuse.
2001 Feb 26
Receptor-mediated regulation of serotonin output in the rat dorsal raphe nucleus: effects of risperidone.
2001 Jan
Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study.
2001 Jan
Acute and long-term treatment of catatonia with risperidone.
2001 Jan
Bodyweight gain with atypical antipsychotics. A comparative review.
2001 Jan
Risperidone-induced cholestatic hepatitis.
2001 Jan
Does risperidone have a place in the treatment of nonschizophrenic patients?
2001 Jan
Clozapine therapy for a patient with a history of Hodgkin's disease.
2001 Jan
Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.
2001 Jan 1
Consistency of atypical antipsychotic superiority to placebo in recent clinical trials.
2001 Jan 1
Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT.
2001 Jan 15
Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon1 subunit.
2001 Jan 15
Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum.
2001 Jan 26
[Viewpoint of schizophrenic patients: a European survey].
2001 Jan-Feb
Effects of dopamine antagonists with different receptor blockade profiles on morphine-induced place preference in male mice.
2001 Jun
Effectiveness of ECT combined with risperidone against aggression in schizophrenia.
2001 Mar
Suspected induction of a pyoderma gangrenosum-like eruption due to sulpiride treatment.
2001 Mar
5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release.
2001 Mar
Fixed-dosed risperidone in mania: an open experimental trial.
2001 Mar
Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
2001 Mar
Pharmacological characterization of locomotor sensitization induced by chronic phencyclidine administration.
2001 Mar
Estrogen - a potential treatment for schizophrenia.
2001 Mar 1
Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study.
2001 Mar 1
Short-term inpatient pharmacotherapy of schizophrenia.
2001 May-Jun
Risperidone addition and psychotic exacerbation.
2001 Winter
Full remission of panic attacks in a schizophrenic patient after switching from haloperidol to risperidone.
2001 Winter
Patents

Sample Use Guides

In Vivo Use Guide
Initial dosing is generally 2 mg/day. Dose increases should then occur at intervals not less than 24 hours, in increments of 1–2 mg/day, as tolerated, to a recommended dose of 4–8 mg/day. Effective dose range - 0.5-16 mg (disease dependent).
Route of Administration: Intramuscular; Oral
In Vitro Use Guide
Measurement of ATP contents in the neuronal cell line showed significantly increased levels after a 24-h treatment with 25 microg/mL risperidone.
Substance Class Chemical
Created
by admin
on Tue Oct 22 00:15:49 UTC 2019
Edited
by admin
on Tue Oct 22 00:15:49 UTC 2019
Record UNII
L6UH7ZF8HC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RISPERIDONE
EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
R-64766
Code English
R 64 766
Code English
RISPERIDONE [WHO-DD]
Common Name English
RISPERIDONE [USAN]
Common Name English
N05AX08
Code English
RISPERIDONE [ORANGE BOOK]
Common Name English
R-64,766
Code English
PERSERIS
Brand Name English
RISPERIDONE [HSDB]
Common Name English
LY03004
Code English
RISPERIDONE [USP-RS]
Common Name English
RISPERIDONE [MART.]
Common Name English
RCN3028
Code English
RISPERDAL
Brand Name English
RCN-3028
Code English
RISPERIDONE [JAN]
Common Name English
3-(2-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL)ETHYL)-6,7,8,9-TETRAHYDRO-2-METHYL-4H-PYRIDO(1,2-A)PYRIMIDIN-4-ONE
Systematic Name English
R-64-766
Code English
RISPERIDONE [EP]
Common Name English
LY-03004
Code English
RISPERIDONE [INN]
Common Name English
RISPERIDONE [USP]
Common Name English
4H-PYRIDO(1,2-A)PYRIMIDIN-4-ONE, 3-(2-(4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)-1-PIPERIDINYL)ETHYL)-6,7,8,9-TETRAHYDRO-2-METHYL-
Systematic Name English
RISPERIDONE [VANDF]
Common Name English
RISPERIDONE [MI]
Common Name English
Classification Tree Code System Code
WHO-ATC N05AX08
Created by admin on Tue Oct 22 00:15:50 UTC 2019 , Edited by admin on Tue Oct 22 00:15:50 UTC 2019
NDF-RT N0000175430
Created by admin on Tue Oct 22 00:15:50 UTC 2019 , Edited by admin on Tue Oct 22 00:15:50 UTC 2019
NCI_THESAURUS C29710
Created by admin on Tue Oct 22 00:15:50 UTC 2019 , Edited by admin on Tue Oct 22 00:15:50 UTC 2019
WHO-VATC QN05AX08
Created by admin on Tue Oct 22 00:15:50 UTC 2019 , Edited by admin on Tue Oct 22 00:15:50 UTC 2019
LIVERTOX 852
Created by admin on Tue Oct 22 00:15:50 UTC 2019 , Edited by admin on Tue Oct 22 00:15:50 UTC 2019
FDA ORPHAN DRUG 326110
Created by admin on Tue Oct 22 00:15:50 UTC 2019 , Edited by admin on Tue Oct 22 00:15:50 UTC 2019
Code System Code Type Description
ChEMBL
CHEMBL85
Created by admin on Tue Oct 22 00:15:50 UTC 2019 , Edited by admin on Tue Oct 22 00:15:50 UTC 2019
PRIMARY
EPA CompTox
106266-06-2
Created by admin on Tue Oct 22 00:15:50 UTC 2019 , Edited by admin on Tue Oct 22 00:15:50 UTC 2019
PRIMARY
HSDB
106266-06-2
Created by admin on Tue Oct 22 00:15:50 UTC 2019 , Edited by admin on Tue Oct 22 00:15:50 UTC 2019
PRIMARY
MERCK INDEX
M9631
Created by admin on Tue Oct 22 00:15:50 UTC 2019 , Edited by admin on Tue Oct 22 00:15:50 UTC 2019
PRIMARY Merck Index
PUBCHEM
5073
Created by admin on Tue Oct 22 00:15:50 UTC 2019 , Edited by admin on Tue Oct 22 00:15:50 UTC 2019
PRIMARY
WIKIPEDIA
RISPERIDONE
Created by admin on Tue Oct 22 00:15:50 UTC 2019 , Edited by admin on Tue Oct 22 00:15:50 UTC 2019
PRIMARY
MESH
D018967
Created by admin on Tue Oct 22 00:15:50 UTC 2019 , Edited by admin on Tue Oct 22 00:15:50 UTC 2019
PRIMARY
INN
6085
Created by admin on Tue Oct 22 00:15:50 UTC 2019 , Edited by admin on Tue Oct 22 00:15:50 UTC 2019
PRIMARY
LactMed
106266-06-2
Created by admin on Tue Oct 22 00:15:50 UTC 2019 , Edited by admin on Tue Oct 22 00:15:50 UTC 2019
PRIMARY
EVMPD
SUB10335MIG
Created by admin on Tue Oct 22 00:15:50 UTC 2019 , Edited by admin on Tue Oct 22 00:15:50 UTC 2019
PRIMARY
CAS
106266-06-2
Created by admin on Tue Oct 22 00:15:50 UTC 2019 , Edited by admin on Tue Oct 22 00:15:50 UTC 2019
PRIMARY
RXCUI
35636
Created by admin on Tue Oct 22 00:15:50 UTC 2019 , Edited by admin on Tue Oct 22 00:15:50 UTC 2019
PRIMARY RxNorm
NCI_THESAURUS
C29416
Created by admin on Tue Oct 22 00:15:50 UTC 2019 , Edited by admin on Tue Oct 22 00:15:50 UTC 2019
PRIMARY
IUPHAR
96
Created by admin on Tue Oct 22 00:15:50 UTC 2019 , Edited by admin on Tue Oct 22 00:15:50 UTC 2019
PRIMARY
DRUG BANK
DB00734
Created by admin on Tue Oct 22 00:15:50 UTC 2019 , Edited by admin on Tue Oct 22 00:15:50 UTC 2019
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
BINDER->LIGAND
TARGET -> AGONIST
SHORT-ACTING
TARGET -> AGONIST
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE ACTIVE -> PARENT
MAJOR
PLASMA
METABOLITE ACTIVE -> PARENT
in vitro mediators are CYP2D6 and CYP3A4
MAJOR
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
not more than the area of the principal peak in the chromatogram obtained with reference solution (b)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
not more than the area of the principal peak in the chromatogram obtained with reference solution (b)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
not more than the area of the principal peak in the chromatogram obtained with reference solution (b)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
not more than the area of the principal peak in the chromatogram obtained with reference solution (b)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
not more than the area of the principal peak in the chromatogram obtained with reference solution (b)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY